Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
Tóm tắt
The rate of development of new orphan drugs continues to grow. As a result, reimbursing orphan drugs on an exceptional basis is increasingly difficult to sustain from a health system perspective. An understanding of the value that societies attach to providing orphan drugs at the expense of other health technologies is now recognised as an important input to policy debates. The aim of this work was to scope the social value arguments that have been advanced relating to the reimbursement of orphan drugs, and to locate these within a coherent decision-making framework to aid reimbursement decisions in the presence of limited healthcare resources. A scoping review of the peer reviewed and grey literature was undertaken, consisting of seven phases: (1) identifying the research question; (2) searching for relevant studies; (3) selecting studies; (4) charting, extracting and tabulating data; (5) analyzing data; (6) consulting relevant experts; and (7) presenting results. The points within decision processes where the identified value arguments would be incorporated were then located. This mapping was used to construct a framework characterising the distinct role of each value in informing decision making. The scoping review identified 19 candidate decision factors, most of which can be characterised as either value-bearing or ‘opportunity cost’-determining, and also a number of value propositions and pertinent sources of preference information. We were able to synthesize these into a coherent decision-making framework. Our framework may be used to structure policy discussions and to aid transparency about the values underlying reimbursement decisions for orphan drugs. These values ought to be consistently applied to all technologies and populations affected by the decision.
Tài liệu tham khảo
Haffner ME. Adopting orphan drugs—two dozen years of treating rare diseases. N Engl J Med. 2006;354:445–7.
Braun MM, Farag-El-Massah S, Xu K, Coté TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov. 2010;9:519–22.
Dunoyer M. Accelerating access to treatments for rare diseases. Nature. 2011;10:475–6.
Food and Drug Administration. Developing products for rare diseases and conditions. Available from: http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm. Accessed 13 Nov 2014.
Food and Drug Administration. Orphan drug regulations. Washington DC; 2013. Available from: http://www.gpo.gov/fdsys/pkg/FR-2013-06-12/pdf/2013-13930.pdf. Accessed 13 Nov 2014.
Salari K, Watkins H, Ashley EA. Personalized medicine: Hope or hype? Eur Heart J. 2012;33:1564–70.
Reeves A, McKee M, Basu S, Stuckler D. The political economy of austerity and healthcare: cross-national analysis of expenditure changes in 27 European nations 1995–2011. Health Policy. 2014;115:1–8.
Stafinski T, Menon D, Davis C, McCabe C. Role of centralized review processes for making reimbursement decisions on new health technologies in Europe. Clin Outcomes Res. 2011;3:117–86.
Stafinski T, Menon D, Philippon DJ, McCabe C. Health technology funding decision-making processes around the world: the same, yet different. Pharmacoeconomics. 2011;29:475–95.
Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
Drummond M, Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ. 2014;15:335–40.
Stafinski T, Menon D, McCabe C, Philippon DJ. To fund or not to fund: development of a decision-making framework for the coverage of new health technologies. Pharmacoeconomics. 2011;29:771–80.
Hutchings A, Schey C, Dutton R, Achana F, Antonov K. Estimating the budget impact of orphan drugs in Sweden and France 2013–2020. Orphanet J Rare Dis. 2014;9:22.
Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010–2020. Orphanet J Rare Dis. 2011;27:62.
Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74.
Mays N, Roberts E, Popay J. Synthesising research evidence. In: Fulop N, Allen P, Clarke A, Black N, editors. Methods for studying the delivery and organisation of health services. London: Routledge; 2001: p. 188–220.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ. 2005;331:1016–9.
McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26:733–44.
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32.
PRISM Group. Promoting rare-disease innovations through sustainable mechanisms (PRISM). 2014. Available from: http://www.prismfive.org. Accessed 13 Nov 2014.
Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG, editors. Anaylsing qualitative data. London: Routledge; 1994. p. 173–94.
Pawson R. Evidence-based policy: in search of a method. Evaluation. 2002;8:157–81.
Bryman A, Burgess R. Analyzing qualitative data. London: Routledge; 1994. p. 232.
Oliver S. Making research more useful: integrating different perspectives and different methods. In: Oliver S, Peersman G, editors. Useful Research for Effective Health Promotion. Buckingham: Open University Press; 2001. p. 167–79.
Barrett P, Alagely A, Topol E. Cystic fibrosis in an era of genomically guided therapy. Hum Mol Genet. 2012;21:R66–71.
Clarke JT. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. Can Med Assoc J. 2006;174:189–90.
Clarke J, Bell C, Coyle D, Stevenson H, Evans G, Martin M, et al. A policy framework for funding drugs for rare diseases. Value Health. 2009;12(7):A243.
Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008;336:251–4.
Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ. 2010;13:295–301.
Desser AS. Prioritizing treatment of rare diseases: a survey of preferences of Norwegian doctors. Soc Sci Med. 2013;94:56–62.
Dickson P, Pariser A, Groft S, Ishihara R, McNeil D, Tagle D, et al. Research challenges in central nervous system manifestations of inborn errors of metabolism. Mol Genet Metab. 2011;102:326–38.
Drakulich A. Global healthcare on the ground: NIH aims to help treat 200 rare diseases. Pharm Technol. 2011;35:22.
Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23:36–42.
Garattini S. Time to revisit the orphan drug law. Eur J Clin Pharmacol. 2012;68:113.
Gupta S. Rare diseases : Canada’s “research orphans”. Open Med. 2012;6:23–7.
Hughes D, Tunnage B, Yeo S. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM Int J Med. 2005;98:829–36.
Hutchings A, Ethgen O, Schmitt C, Rollet P. Defining elements of value for rare disease treatments. Value Health. 2012;15(4):A31.
Joppi R, Bertele’ V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol. 2013;69:1009–24.
Kanavos P, Nicod E. What is wrong with orphan drug policies? Suggestions for ways forward. Value Health. 2012;15:1182–4.
Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011;305:2320–6.
Largent EA, Pearson SD. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases. Hastings Cent Rep. 2012;42:27–34.
Laupacis A. Evidence and values: requirements for public reimbursement of drugs for rare diseases: a case study in oncology. Can J Clin Pharmacol. 2009;16:e282–4.
Liang BA, Mackey T. Reforming off-label promotion to enhance orphan disease treatment. Science. 2010;327:273–4.
Luisetti M, Balfour-Lynn IM, Johnson SR, Miravitlles M, Strange C, Trapnell BC, et al. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. Respir Med. 2012;106:759–68.
Matthews J, Glass L. The effect of market-based economic factors on the adoption of orphan drugs across multiple countries. Ther Innov Regul Sci. 2013;47:226–34.
Mavris M, Le Cam Y. Involvement of patient organisations in research and development of orphan drugs for rare diseases in Europe. Mol Syndromol. 2012;3:237–42.
McCabe C, Stafinski T, Menon D. Is it time to revisit orphan drug policies? BMJ. 2010;341:c4777.
Meekings KN, Williams CSM, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012;17:660–4.
Mentzakis E, Stefanowska P, Hurley J. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. Health Econ Policy Law. 2011;6:405–33.
Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res. 2012;12:23–9.
Moberly T. Rationing and access to orphan drugs. Pharm J. 2005;275:569–70.
Owen A, Spinks J, Meehan A, Robb T, Hardy M, Kwasha D, et al. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. J Med Econ. 2008;11:235–43.
Picavet E, Dooms M, Cassiman D, Simoens S. Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy. 2011;9:275–9.
Picavet E, Cassiman D, Simoens S. Evaluating and improving orphan drug regulations in Europe: a Delphi policy study. Health Policy. 2012;108:1–9.
Pinxten W, Denier Y, Dooms M, Cassiman J, Dierickx K. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation. J Med Ethics. 2012;38:148–53.
Prevot J, Watters D. HTA’s and access to rare diseases therapies: the view from the PID community. Pharm Policy Law. 2011;11:177–81.
Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87:935–43.
Stolk P, Willemen MJC, Leufkens HGM. Rare essentials: drugs for rare diseases as essential medicines. Bull World Health Organ. 2006;84:745–51.
Sullivan SD. The promise of specialty pharmaceuticals: are they worth the price? J Manag Care Pharm. 2008;14:S3–6.
Valverde J-L. Editorial. Pharm Policy Law. 2011;13:115–6.
Wild C, Hintringer K, Nachtnebel A. Orphan drugs in oncology. Pharm Policy Law. 2011;13:223–32.
Winquist E, Bell CM, Clarke JTR, Evans G, Martin J, Sabharwal M, et al. An evaluation framework for funding drugs for rare diseases. Value Health. 2012;15:982–6.
Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy. 2007;12:56–8.
Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ. 2011;20:2–15.
Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the NICE cost effectiveness threshold. York: Centre for Health Economics, York University; 2013. Report No. 81.
Endrei D, Molics B, Ágoston I. Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary. Value Health. 2014;17(4):487–9.
Mitton C, Dionne F, Damji R, Campbell D, Bryan S. Difficult decisions in times of constraint: criteria based resource allocation in the Vancouver Coastal Health Authority. BMC Health Serv Res. 2011;11:169.
Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health. 2013;16:1163–9.
Linley WG, Hughes DA. Societal views on nice, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ. 2013;22:948–64.